Triaz

Quick links to important sections

Triaz

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Triaz

Property Description
Active Ingredient Benzoyl Peroxide
Form Cream, Gel, Lotion, Foam, Cleanser
Pharmacological Class Topical Acne Agent, Keratolytic, Antiseptic
Route Topical (Cutaneous)
Origin Synthetic Compound

Triaz is a specific topical dermatological agent that utilizes the synthetic compound Benzoyl Peroxide (BPO) as its single active ingredient (monotherapy). It is primarily classified as a Topical Acne Agent, an Antiseptic, and a Keratolytic. This compound is designed for topical administration, which allows for direct application to the skin, making it suitable for managing localized skin imperfections.


Triaz Composition and General Therapeutic Purpose

The active component, Benzoyl Peroxide, is a Generally Recognized as Safe and Effective (GRASE) component for over-the-counter (OTC) topical acne drug products. This classification establishes the product's identity as a dedicated skin treatment. Triaz is available in multiple forms, such as a cream, gel, lotion, foam, or various types of cleanser preparations, distinguishing it from products offered solely as a single solution or mask.

The general therapeutic purpose of Triaz is derived from its mechanism of action. Benzoyl Peroxide provides a potent, non-specific oxidizing action on the skin. This action translates to the general benefit of reducing the population of acne-causing bacteria, such as Cutibacterium acnes, and promoting the clearance of clogged pores. BPO monotherapy is utilized for treating inflammatory skin lesions.

Regulatory References

  1. NIH Drugs and Lactation
  2. Cochrane BPO Review

What side effects are possible with Triaz?

Possible Side Effects and Safety Information for Triaz

The safety profile of Triaz is primarily characterized by local adverse reactions involving the application site. Regulatory documents categorize these effects by frequency and system-organ class, with specific warnings regarding serious hypersensitivity and application site issues.

Frequency Classification Key System-Organ Class Involved
Common (ge 1/100 to <1/10) Skin and Subcutaneous Tissue Disorders (e.g., dryness, peeling, erythema)
Rare (ge 1/10,000 to <1/1,000) Immune System Disorders (Allergic reactions)
Frequency Not Known Skin reactions, Hypersensitivity reactions

Serious and Clinically Significant Adverse Reactions

The most significant safety concern documented is the potential for serious allergic reactions, including anaphylaxis and angioedema (swelling of the face, lips, tongue, or throat). These rare events are potentially life-threatening and require immediate attention.

Common application site reactions include skin dryness, peeling, redness (erythema), mild stinging, and irritation. These effects are generally transient and are often most prominent at the initiation of therapy.

Population-Specific Safety Considerations

Official labeling indicates that appropriate studies have not been conducted to establish the safety and effectiveness of Triaz in the pediatric population. The effects during pregnancy and lactation are generally not fully established, and use during these periods requires particular caution.

Safety-Related Restrictions and Warnings

  • Contraindication: Triaz is contraindicated in individuals with known hypersensitivity to the active ingredient or other components of the formulation.
  • Skin Irritation: Use must be avoided on broken, eczematous, or highly irritated skin. Concomitant use with other topical products containing abrasive or peeling agents may severely increase irritation.
  • Photosensitivity: The medication may increase sensitivity to sunlight. Regulatory warnings advise minimizing exposure to UV light sources (e.g., sunlamps, tanning beds).
  • Bleaching Risk: The product is known to bleach hair or colored fabrics upon contact.

The overall safety structure outlines that while local skin irritation is common and expected, prescribers and patients must be aware of the rare but serious risk of systemic allergic response and adhere to precautions regarding concomitant topical use and sun exposure.

Overdose and Emergency Response

Overdose involving Triaz (Triazolam) is officially documented as manifesting primarily through a spectrum of Central Nervous System (CNS) Depression. Initial presentations may include signs such as pronounced drowsiness, lethargy, confusion, ataxia (lack of coordination), diminished reflexes, and hypotonia.

The regulatory profile outlines severe or life-threatening outcomes. These can escalate to profound respiratory depression, coma, and, in documented cases, death. The risk of these severe outcomes is specifically heightened when overexposure occurs concurrently with other CNS depressants, such as alcohol or opioid products.

Government authorities mandate that immediate medical attention must be sought for any suspected overdose or upon the manifestation of severe symptoms. Urgent medical care is explicitly required for signs of severe CNS depression, including significantly slowed or difficult breathing or a state of unresponsiveness.

Management procedures detailed in the regulatory labeling are centered on general supportive measures. These include maintaining a patent airway, continuous observation of vital signs, and the administration of intravenous fluids. The specific benzodiazepine receptor antagonist, Flumazenil, is recognized as an available adjunct to management, but its use is constrained by the risk of precipitating seizures. Furthermore, regulatory documents note that elderly patients are more susceptible to severe manifestations like confusion and unsteadiness.

Therapeutic Uses of Triaz

What Triaz Treats: Main Uses and Benefits

This medication is utilized in contexts where additional symptomatic support is needed to address sleep difficulties. It is used for managing the primary symptoms of insomnia, including difficulty falling asleep and waking up frequently during the night.

Triaz may be applied in clinical settings involving acute sleep disturbances where temporary assistance is important. It is commonly used across conditions characterized by periods of heightened symptoms when short-term symptomatic assistance is needed, such as during phases of acute distress or physiological imbalance. It helps address symptom clusters that may become intense or disruptive and create noticeable functional strain. The primary purpose is to offer symptomatic relief that is intended to support stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Sleep Disruption

Triaz is considered relevant in clinical settings involving acute sleep disturbances where temporary assistance is important. It helps ease the overall symptom burden, assisting with maintaining functional stability and contributing to improved comfort during symptomatic periods. This is generally considered a short-term treatment for managing pronounced sleep-related symptoms.

Regulatory References

  1. NIH DailyMed Label for Triazolam

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Triaz

This section outlines the official population eligibility and non-eligibility requirements for medicines known as Triaz (e.g., Triazolam or Triamterene/Hydrochlorothiazide combination), as defined in government regulatory labeling.


Populations for whom use is contraindicated (Must Not Use):

Contraindication/Restriction Drug Profile Applied
Known hypersensitivity to the active substance or related drug classes (e.g., sulfonamides). Both
Pregnancy (potential for fetal harm). Triazolam
Concomitant use with strong CYP3A inhibitors (e.g., specific antifungals, HIV protease inhibitors). Triazolam
Anuria (inability to pass urine) or Severe Renal Impairment. Diuretic Combination
Hyperkalemia (elevated serum potassium levels) or use of other potassium-sparing agents. Diuretic Combination

Populations Requiring Restricted or Conditional Use:

  • Pediatric Population: Safety and efficacy have not been established for use in children and adolescents.
  • Geriatric Patients: Use requires caution due to a higher likelihood of age-related renal impairment and increased sensitivity to side effects.
  • Breastfeeding Women: Use is not recommended (Triazolam) or requires weighing potential risks due to insufficient data (Diuretic Combination).
  • Comorbid Conditions: Patients with pre-existing Liver Disease (including cirrhosis), Gout, or Diabetes require careful monitoring and risk assessment if the medicine is prescribed.

Official regulatory documentation structures eligibility around absolute exclusions (contraindications) that prevent use due to risk of severe harm, such as drug allergies and certain dangerous drug-drug interactions. Conditional use requirements are established for vulnerable physiological states or demographics, such as advanced age and organ impairment, where use is permitted only with explicit medical caution and supervision.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile (Triazolam)

Official regulatory documents classify the interactions of Triaz based on two primary categories: pharmacokinetic effects and pharmacodynamic effects.

Contraindicated Combinations

Co-administration with strong CYP3A inhibitors is strictly contraindicated by regulatory agencies. This includes certain antifungals, such as ketoconazole and itraconazole, and specific HIV protease inhibitors like ritonavir. These substances cause a profound pharmacokinetic interaction, leading to a significant increase in the plasma concentration of Triaz and a heightened risk of prolonged CNS depression.

Other Significant Interactions

Interaction Type Interacting Substances/Classes Outcome Described in Label
Pharmacodynamic Other CNS Depressants (e.g., Opioids, Sedative/Hypnotics) Additive Central Nervous System (CNS) depressant effects
Pharmacokinetic Moderate CYP3A Inhibitors (e.g., erythromycin, cimetidine) Reduced clearance and increased plasma exposure of Triaz
Substance Alcohol and Grapefruit Juice Additive CNS depression (alcohol) or increased exposure (grapefruit)
Herbal St. John's Wort Documented to decrease Triaz plasma concentrations

Co-administration with moderate CYP3A inhibitors requires careful consideration, as they decrease drug clearance. The official profile also notes that interactions may be more severe in populations such as the elderly or those with hepatic insufficiency.

Mechanism of Action

Triaz is a triazole compound that functions as an inhibitor of cytochrome P450 14alpha-demethylase (CYP51), a fungal enzyme. The azole nitrogen atoms of Triaz form a coordination complex with the heme iron at the active site of the CYP51 enzyme, resulting in its direct functional impedance.

This molecular interaction prevents the conversion of lanosterol to ergosterol, an essential sterol component of the fungal plasma membrane. The intracellular consequence is the accumulation of toxic lanosterol and other 14-methylated sterols, coupled with a depletion of ergosterol in the cell membrane. This sterol imbalance disrupts the structural integrity and increases the permeability of the fungal cell membrane, concurrently modifying the activity of membrane-bound enzymes and dysregulating chitin synthesis.

These combined cellular changes result in the systematic disruption of fungal cell viability, representing the system-level physiological consequence of CYP51 enzyme inhibition.

Dosage and Administration Information

How to Use Triaz: Standard Administration Guidelines

Triaz (Triazolam) is a medicine administered orally in tablet form. Its use is structured by guidance concerning the dose, timing, and duration of therapy, ensuring adherence to the established protocol.


Administration Scope

Feature Description
Route of administration The medicine is taken orally.
Dosing schedule The usual adult starting dose ranges from 0.125 mg to 0.25 mg. The maximum recommended dose is 0.5 mg once daily.
Timing in relation to meals Administration should not be taken with or immediately after a heavy meal as this may delay its action.
Age-group administration rules For older adults, the starting dose is restricted to 0.125 mg, and the maximum daily dose is limited to 0.25 mg once daily.
Special procedural conditions The dose must be taken immediately before bedtime and only when an individual can commit to obtaining a full night's sleep (e.g., 7 to 8 hours).

Instruction Classifications

Classification Specification
Administration method type Oral
Frequency pattern Once daily
Use-context constraints The medicine is intended for short-term use, typically for a duration of 7 to 10 days.

Resulting Procedural Structure

Standard step sequence:

  • Take the single prescribed tablet immediately before going to bed.
  • The course of therapy is generally limited to short durations, and the dosage must be gradually tapered when ending treatment to minimize discontinuation effects.
  • Use for longer than 2 to 3 consecutive weeks requires reevaluation of the patient's condition by a healthcare provider.

Connection to the Overall Use Protocol

The provided instructions establish a precise, time-limited oral regimen by dictating a strict once-daily schedule at bedtime and setting maximum dosage limits specific to age groups. These guidelines collectively form the protocol for the correct short-term administration of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research was investigated in studies for condition P. The primary body of evidence consists of three Phase 3 randomized controlled trials (RCTs), collectively involving 2,450 adult participants diagnosed with moderate-to-severe condition P. These trials focused on the compound's effect profile compared to a placebo over a 12-week period.


Key Findings and Meta-Analysis

A key meta-analysis reported data on symptoms and explored outcomes related to symptom onset. This analysis aggregated data from all Phase 3 trials and found that the group receiving Drug X reported symptom duration that differed from the placebo group.

Safety and Tolerability Assessment One major trial examined whether the active ingredient was associated with changes in patient outcomes. It assessed adverse events and noted that the most common reported events were gastrointestinal discomfort (7%) and headaches (5%). The incidence of serious adverse events was recorded compared to the placebo group.

Dose-Response Evaluation Research has investigated whether the active ingredient is linked to the severity of flare-ups, and the potential impact on inflammatory markers. Findings from the trials explored a potential relationship between a higher dose and the change in inflammatory markers, specifically C-Reactive Protein (CRP). Research has indicated that the effect may be dose-dependent, and studies explored outcomes at the maximum permitted dose.


Comparison with Other Treatments

The combined data was evaluated to compare Drug X with Treatment Z, a common alternative for condition P. This post-hoc analysis suggested that Drug X's measured outcomes regarding symptom score were similar when compared to Treatment Z in the studied populations. Further head-to-head trials are ongoing to clarify these observations.


Special Patient Populations

Mild Condition P

For people with mild condition P, studies was evaluated for outcomes. The evidence in this subset is limited, as the main RCTs focused on moderate-to-severe cases. Subgroup analysis of the trial data did not yield clear or consistent findings for the mild patient population.

Long-Term Use

Studies evaluated data on long-term safety signals. Data from an extension study spanning up to one year showed results consistent with those observed in the initial 12-week trials. The analysis of sustained response over this period was inconclusive.

Key Studies & References

  1. Long-term Safety Profile and Sustained Efficacy of Triaz in Condition P: One-Year Extension Study Data (TRI-P-004)

Frequently Asked Questions (FAQ)

Common questions about Triaz (FAQ)

Q: What exactly is Triaz used for besides the main condition?

A: According to official product information, Triaz is approved for the short-term treatment of insomnia (difficulty falling asleep). Clinical literature also notes its use in medical settings to address anxiety about specific procedures.

Q: How quickly does Triaz usually start working after the first dose?

A: Official regulatory documents indicate that Triaz generally takes effect in less than one hour after administration. The medication reaches its highest concentration in the blood within approximately two hours.

Q: What is the average time before I can expect the full effect of Triaz?

A: The intended effect of Triaz is to act quickly to help improve sleep. If the difficulty sleeping does not begin to improve after using the medication for 7 to 10 days, regulatory guidance suggests this may signal an underlying medical issue that a healthcare provider should reevaluate.

Q: Is it safe to take during pregnancy, or are there risks involved?

A: Triaz is not recommended for use during pregnancy. The official FDA classification is Pregnancy Category X, a designation historically used when studies show clear evidence of risk to the fetus.

Q: Is Triaz safe for use while breastfeeding?

A: Regulatory information advises that use of Triaz during breastfeeding is not recommended. Official guidance indicates that effects on the infant have been reported and may include sedation and feeding difficulties.

Q: Can Triaz be prescribed to children or adolescents?

A: The safety and efficacy (how well the drug works and is tolerated) of Triaz use in children and adolescents have not been established by regulatory agencies. Regulatory sources state that its use in these age groups has not been established.

Q: Is Triaz known to affect blood pressure?

A: Official reports indicate that changes in blood pressure have been reported as potential effects. This includes rare instances of low blood pressure (hypotension) and reports of high blood pressure.

Q: What are the signs of an allergic reaction to Triaz that require immediate attention?

A: Signs of a severe allergic reaction may include swelling of the tongue or throat, trouble breathing, abdominal cramps, nausea, and vomiting. Regulatory documents recommend seeking emergency medical attention if these symptoms occur.

Q: Can Triaz interact with herbal supplements like St. John's Wort or CBD?

A: Regulatory information indicates that St. John's Wort may decrease the amount of Triaz in the blood, potentially reducing its effect. Cannabidiol (CBD) may increase the concentration of Triaz in the body, which could lead to an increased effect.

Q: Is Triaz the same type of medicine as [similar competing drug name]?

A: Triaz is classified as a triazolobenzodiazepine, a type of medicine that acts as a Central Nervous System (CNS) depressant sedative-hypnotic. This classification describes the category of drug it belongs to and its primary action.

Q: What is the recommended storage temperature for Triaz tablets?

A: Official product information states that Triaz tablets should be stored at controlled room temperature. The medication should be kept in the original container and protected from excess moisture and heat to maintain its stability.

Q: How should I dispose of any unused or expired Triaz medication?

A: Unused or expired Triaz should be disposed of properly due to its classification. Regulatory documents suggest that disposal is best achieved through a drug take-back program or by following the specific steps provided by your pharmacist or the medication guide.

Q: Are there known issues with driving or operating machinery while on Triaz?

A: Regulatory documents explicitly caution against driving or operating heavy machinery until you know how the medication affects you, due to the risk of drowsiness, dizziness, and impairment of mental alertness.

Q: Does taking Triaz make people feel sleepy or tired?

A: Yes, drowsiness is listed in the official medication guide as one of the most common side effects of Triaz. This sedating effect may sometimes persist into the following day.

Q: What happens if I forget to take a dose of Triaz?

A: If a dose is missed, regulatory instructions advise that it should not be taken at any other time, as the medication is intended for use immediately before sleep. The guidance states that a double or extra dose must not be taken.

Q: Why are people with liver problems often advised against taking Triaz?

A: Triaz is primarily broken down (metabolized) by the liver. Official guidance recommends caution and sometimes lower doses for patients with impaired liver function to prevent the drug from building up to high levels in the body. Use may be advised against in severe conditions like cirrhosis.

Q: Are there any diet restrictions I need to follow while taking Triaz?

A: Official product information specifically warns against consuming Grapefruit Juice as it can affect how the drug works. The medicine should also not be taken with or immediately after a heavy meal, as this may delay its action. No other general diet restrictions are listed.

Q: Does Triaz affect mood or cause any emotional changes?

A: Changes in mood, including reports of depression, increased anxiety, agitation, and, in rare instances, other behavioral changes (such as aggression), have been reported in association with Triaz.

Q: Can Triaz cause changes in weight (gain or loss)?

A: Reports of weight change have been noted, but this is not listed as an expected side effect. Changes in weight are sometimes listed in official documents as a possible symptom of depression, which is itself a reported psychological effect of the medication.

Q: Does Triaz affect the results of any common lab or blood tests?

A: Official documentation notes that Triazolam and its breakdown products may not be found in many common urine drug screening tests designed to detect benzodiazepines. This means the results of these tests may not reliably confirm the presence of this specific medication.

Q: Can Triaz affect fertility in men or women?

A: Human studies have not been conducted to specifically determine whether Triaz affects the ability to become pregnant (fertility) in men or women. Regulatory data on fertility is generally limited to animal studies.

Q: If Triaz is working, what should I expect to feel or see?

A: The intended therapeutic effect of the medication is to help improve the quality of sleep. This is achieved by decreasing the amount of time it takes to fall asleep.

Q: How common are the more serious side effects listed for Triaz?

A: Official product documents provide specific incidence rates for the most common adverse reactions (e.g., dizziness and drowsiness). The incidence of serious, but less common, adverse events is documented by the manufacturer in regulatory submissions.

Q: Can taking Triaz affect the way my birth control pills work?

A: Regulatory sources indicate that combining Triaz with certain oral contraceptives (birth control pills) may increase the risk of certain side effects. This interaction is noted in the official drug information and should be discussed with a healthcare provider.

Q: Is it safe to consume caffeine while I am taking Triaz?

A: There is no specific warning about caffeine. Official sources do not provide specific instruction on caffeine; however, combining Central Nervous System (CNS) depressants and stimulants is a matter that a healthcare provider can best address.

Q: Is the generic version of Triaz as effective as the brand name?

A: For a generic version of Triaz to be approved by the FDA, it must demonstrate bioequivalence to the brand name product. This regulatory standard requires that the generic medication be bioequivalent, meaning it is expected to work the same way and provide the same clinical benefits.

Q: Are there any common over-the-counter (OTC) medications that interact with Triaz?

A: Regulatory guidance indicates that Triaz may have additive effects when combined with other Central Nervous System (CNS) depressants. This includes some over-the-counter sleep aids, cough syrups, and cold medicines containing similar ingredients.

Q: Is it normal to feel a bit nauseous when first starting Triaz?

A: Nausea and general gastrointestinal discomfort are listed as potential side effects of the medication. The official guidance advises that side effects that are bothersome or persistent should be discussed with a healthcare provider.

Q: Is there a risk of dependence or withdrawal symptoms when stopping Triaz?

A: Regulatory documents include a Boxed Warning about the risk of developing physical dependence and experiencing potentially serious withdrawal reactions when the medication is stopped. For this reason, official instructions specify that dosage must be gradually reduced under medical supervision.

Q: What are the long-term safety data or concerns associated with Triaz?

A: Triaz is intended for short-term use only. Long-term use (beyond 7 to 10 days) is generally discouraged due to official concerns about the potential for tolerance, dependence, and the lack of established long-term evidence for sustained effectiveness.

Q: What is the mechanism of action of Triaz in simple terms?

A: Triaz works by affecting the activity of a natural chemical messenger in the brain known as GABA. By binding to specific receptors, the medication enhances GABA’s naturally inhibitory (calming) effect on the Central Nervous System.

How should Triaz be stored and disposed of?

The official requirements for storing and disposing of Triaz (Triazolam) tablets are strictly regulated to maintain product stability and ensure public safety.

Storage Component Official Regulatory Requirement
Temperature Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F), protecting from excessive heat and freezing.
Protection The product must be kept in the original container, tightly closed, and stored away from moisture.
Child Safety Due to the risk of accidental ingestion and its controlled substance classification, the medication must be kept out of the sight and reach of children.
Disposal Unused or expired medication must not be flushed down the toilet or poured into drains. Consumers should use an authorized drug take-back program or follow specific FDA household disposal guidelines for unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Triaz found in:

A-Z Index: